Retatrutide, a novel dual-acting glucose-responsive incretin analog, represents a significant leap in peptide therapeutics for the treatment of type 2 diabetes and, increasingly, weight issues. Unlike many existing medicinal interventions, retatrutide merges the actions of a GLP-1 receptor activator and a GIP receptor stimulant, offering a more hol